The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Beckwith Wiedemann syndrome chromosome region 1 candidate protein C
Beckwith-Wiedemann syndrome chromosomal region 1 candidate gene C protein
Imprinted in placenta and liver
Imprinted in placenta and liver protein
p17 Beckwith Wiedemann region 1C
p17-Beckwith-Wiedemann region 1 C
Pleckstrin homology like domain family A member 2
Pleckstrin homology-like domain family A member 2
Tumor suppressing STF cDNA 3 protein
Tumor suppressing subchromosomal transferable fragment candidate gene 3 protein
Tumor suppressing subchromosomal transferable fragment cDNA 3
Tumor suppressing subtransferable candidate 3
Tumor supressing STF cDNA 3
Tumor-suppressing STF cDNA 3 protein
Tumor-suppressing subchromosomal transferable fragment candidate gene 3 protein
Plays a role in regulating placenta growth. May act via its PH domain that competes with other PH domain-containing proteins, thereby preventing their binding to membrane lipids.
Expressed in placenta and adult prostate gland. In placenta, it is present in all cells of the villous cytotrophoblast. The protein is absent in cells from hydatidiform moles. Hydatidiform mole is a gestation characterized by abnormal development of both fetus and trophoblast. The majority of hydatidiform moles are associated with an excess of paternal to maternal genomes and are likely to result from the abnormal expression of imprinted genes (at protein level). Expressed at low levels in adult liver and lung, and fetal liver. Expressed in adult brain and neuroblastoma, medullablastoma and glioblastoma cell lines.
Belongs to the PHLDA2 family. Contains 1 PH domain.
The PH domain binds phosphoinositides with a broad specificity. It may compete with the PH domain of some other proteins, thereby interfering with their binding to phosphatidylinositol 4,5-bisphosphate (PIP2) and phosphatidylinositol 3,4,5-triphosphate (PIP3).